0001104659-21-151823.txt : 20211220 0001104659-21-151823.hdr.sgml : 20211220 20211220174915 ACCESSION NUMBER: 0001104659-21-151823 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211220 FILED AS OF DATE: 20211220 DATE AS OF CHANGE: 20211220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Goel Shubh CENTRAL INDEX KEY: 0001787942 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32295 FILM NUMBER: 211506282 MAIL ADDRESS: STREET 1: 1100 MAXWELL, #522 CITY: HOBOKEN STATE: NJ ZIP: 07030 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FENNEC PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0001211583 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: PO BOX 13628 STREET 2: 68 TW ALEXANDER DRIVE CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: (919) 636-4530 MAIL ADDRESS: STREET 1: PO BOX 13628 STREET 2: 68 TW ALEXANDER DRIVE CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: FENNEC PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20140903 FORMER COMPANY: FORMER CONFORMED NAME: ADHEREX TECHNOLOGIES INC DATE OF NAME CHANGE: 20021223 4 1 tm2135965-3_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-12-20 0 0001211583 FENNEC PHARMACEUTICALS INC. FENC 0001787942 Goel Shubh 68 TW ALEXANDER DRIVE, PO BOX 13628 DURHAM NC 27709 0 1 0 0 Chief Commercial Officer Stock Option (right to buy) 4.08 2021-12-20 4 A 0 75000 0 A 2031-12-20 Common Shares 75000 75000 D Restricted Share Unit (right to receive value of a share) 0 2021-12-20 4 A 0 37500 0 A 2031-12-20 Common Shares 37500 37500 D On December 20, 2021, Shubh Goel was granted an incentive stock option to purchase 75,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. On December 20, 2021, Shubh Goel was granted restricted share units to receive 37,500 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. Item vests 100% upon FDA approval of PEDMARKTM. /s/ Shubh Goel, Chief Commercial Officer 2021-12-20